Supplemental Table 8. Least Squares Means and Test of Main Effects (adjusted by Interaction of Valve Type and Treatment Arm, and High/Low BL Lesion Volume) ITT Population – Mean Estimate Effect (95% CI) Least Squares Mean new lesion volume (mm3), Protected territories 162.8 Control Arm (107.9, 245.5) 0.0248 83.3 Device Arm (55.0, 126.1) Least Squares Mean new lesion volume (mm3), all territories 311.1 Control Arm (212.2, 456.3) 0.0500 180.6 Device Arm (122.7, 265.8) Least Squares Mean new lesion volume (mm3), Protected territories 172.6 Evolut R (n=45) (103.7, 287.2) 113.6 SAPIEN 3 (n=108) 0.166 (81.8, 157.8) 80.5 SAPIEN XT (n=29) (42.6, 152.0) Squares Mean new lesion volume (mm3), all territories 408.0 Evolut R (n=45) (253.9, 655.6) 228.2 SAPIEN 3 (n=108) 0.021 (168.0, 309.9) 143.1 SAPIEN XT (n=29) (79.1, 258.7) Note: In to get stable TAVR device estimates from the model, Medtronic CoreValve (which only contributed 7 patients with imaging follow-up) was excluded from the analysis.
Supplemental Table 8. Least Squares Means and Test of Main Effects (adjusted by Interaction of Valve Type and Treatment Arm, and High/Low BL Lesion Volume) – ITT Population Effect Mean Estimate (95% CI) Least Squares Mean new lesion volume (mm3), Protected territories Control Arm 162.8 (107.9, 245.5) 0.0248 Device Arm 83.3 (55.0, 126.1) Least Squares Mean new lesion volume (mm3), all territories Control Arm 311.1 (212.2, 456.3) 0.0500 Device Arm 180.6 (122.7, 265.8) Least Squares Mean new lesion volume (mm3), Protected territories Evolut R (n=45) 172.6 (103.7, 287.2) 0.166 SAPIEN 3 (n=108) 113.6 (81.8, 157.8) SAPIEN XT (n=29) 80.5 (42.6, 152.0) Squares Mean new lesion volume (mm3), all territories Evolut R (n=45) 408.0 (253.9, 655.6) 0.021 SAPIEN 3 (n=108) 228.2 (168.0, 309.9) SAPIEN XT (n=29) 143.1 (79.1, 258.7) Note: In to get stable TAVR device estimates from the model, Medtronic CoreValve (which only contributed 7 patients with imaging follow-up) was excluded from the analysis.
1-s2.0-S0735109716367687-mmc1.docx